Objective: Fabry's disease (FD) is a genetic disorder of lysosomal storage characterized by the intralysosomal accumulation of globotriaosylceramide (Gb3). This genetic mutation causes a total or partial deficit of the α-galactosidase (GAL) enzyme activity. FD has an incidence of 1:40000-60000 born alive. Its prevalence is higher in specific pathological conditions like chronic kidney disease (CKD). The aim of this study was to evaluate the FD prevalence in Italian renal replacement therapy (RRT) patients from Lazio region. Patients and methods: 485 patients in RRT (hemodialysis, peritoneal dialysis, and kidney transplantation) were recruited. The screening test was performed on venous blood sample. The latter was analyzed using specific FD diagnostic kit, based on the analysis of dried blood spots on filter paper. Results: We found 3 cases of positivity to FD (1 female and 2 males). In addition, 1 male patient was identified with biochemical alteration indicative of GAL enzyme deficiency with a genetic variant of the GLA gene of unknown clinical significance. The FD prevalence in our population was 0.60% (1 case out 163), it rises to 0.80% (1 case out of 122) if the genetic variant of unknown clinical significance is considered. Comparing the three subpopulations, we observed a statistically significant difference in GAL activity in transplanted patients compared to dialysis patients (p<0.001). Conclusions: Considering the presence of an enzyme replacement therapy able to modify FD clinical history, it is essential to try to implement FD early diagnoses. However, the screening is too expensive to be extended on large scale, due to the low prevalence of the pathology. The screening should be performed on high-risk populations.

Marrone, G., Angelico, R., Di Lauro, M., Sargentini, E., Manzia, T.m., Tisone, G., et al. (2023). Screening of Fabry Disease of patients in renal replacement therapy in a population from Lazio (Italy). EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 27(7), 3134-3141 [10.26355/eurrev_202304_31947].

Screening of Fabry Disease of patients in renal replacement therapy in a population from Lazio (Italy)

Angelico, R;Di Lauro, M;Manzia, T M;Tisone, G;Mitterhofer, A P;Della Morte Canosci, D;Tesauro, M;Di Daniele, N;Noce, A
2023-04-01

Abstract

Objective: Fabry's disease (FD) is a genetic disorder of lysosomal storage characterized by the intralysosomal accumulation of globotriaosylceramide (Gb3). This genetic mutation causes a total or partial deficit of the α-galactosidase (GAL) enzyme activity. FD has an incidence of 1:40000-60000 born alive. Its prevalence is higher in specific pathological conditions like chronic kidney disease (CKD). The aim of this study was to evaluate the FD prevalence in Italian renal replacement therapy (RRT) patients from Lazio region. Patients and methods: 485 patients in RRT (hemodialysis, peritoneal dialysis, and kidney transplantation) were recruited. The screening test was performed on venous blood sample. The latter was analyzed using specific FD diagnostic kit, based on the analysis of dried blood spots on filter paper. Results: We found 3 cases of positivity to FD (1 female and 2 males). In addition, 1 male patient was identified with biochemical alteration indicative of GAL enzyme deficiency with a genetic variant of the GLA gene of unknown clinical significance. The FD prevalence in our population was 0.60% (1 case out 163), it rises to 0.80% (1 case out of 122) if the genetic variant of unknown clinical significance is considered. Comparing the three subpopulations, we observed a statistically significant difference in GAL activity in transplanted patients compared to dialysis patients (p<0.001). Conclusions: Considering the presence of an enzyme replacement therapy able to modify FD clinical history, it is essential to try to implement FD early diagnoses. However, the screening is too expensive to be extended on large scale, due to the low prevalence of the pathology. The screening should be performed on high-risk populations.
apr-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/09 - MEDICINA INTERNA
Settore MED/18 - CHIRURGIA GENERALE
English
Marrone, G., Angelico, R., Di Lauro, M., Sargentini, E., Manzia, T.m., Tisone, G., et al. (2023). Screening of Fabry Disease of patients in renal replacement therapy in a population from Lazio (Italy). EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 27(7), 3134-3141 [10.26355/eurrev_202304_31947].
Marrone, G; Angelico, R; Di Lauro, M; Sargentini, E; Manzia, Tm; Tisone, G; Mitterhofer, Ap; Della Morte Canosci, D; Tesauro, M; Di Daniele, N; Noce, ...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Screening of Fabry Disease.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 463.95 kB
Formato Adobe PDF
463.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/323122
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact